Pharsight

1. Arazlo patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11311482	June, 2023	Notice of Filing Date Accorded	Bausch Health Ireland Limited et al.	Padagis Israel Pharmaceuticals Ltd. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6517847	BAUSCH	Topical gel delivery system	Aug, 2020 (3 years ago)
US11679116	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US11311482	BAUSCH	Topical compositions and methods for treating skin diseases	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 18, 2022

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00045	12 May, 2022	1		11 May, 2038

Strength	Dosage	Availability
0.045%	LOTION;TOPICAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent

US10688071	February, 2015	Decision	Leon LOUPENOK
US10568859	April, 2014	Decision	Leon LOUPENOK

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688071	MAYNE PHARMA	Topical foam composition	Feb, 2030 (5 years from now)
US8808716	MAYNE PHARMA	Topical foam composition	Feb, 2030 (5 years from now)
US10568859	MAYNE PHARMA	Topical foam composition	Feb, 2030 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	May 11, 2015

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
0.1%	AEROSOL, FOAM;TOPICAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5914334	ALLERGAN	Stable gel formulation for topical treatment of skin conditions	Jun, 2014 (9 years ago)
US6258830	ALLERGAN	Stable gel formulation for topical treatment of skin conditions	Jun, 2014 (9 years ago)

Market Authorisation Date: 13 June, 1997

Treatment: Stable gel formulation for topical treatment of skin conditions

Dosage: GEL;TOPICAL